Loading...

Media
< Back

Press Releases

Media Statements

Media Library
Our 2023 Integrated Annual Report is live!
Investors
Partnering
Careers
- Careers
- Careers
- Working at Ipsen
- Culture

Loading...
English EN Français FR EN
- EnglishEN
- FrançaisFR
Global
< Back
- Global EN FR
- Annual Report EN FR
United States

Brazil

Canada

Mexico

Australia

China

Singapore

South Korea

Japan

Belgium

Ukraine

UK

Germany

France

Nordics

Greece

Italy

Netherlands

Spain

Poland

Russia

Czech Republic

Switzerland

Home
Company
- Company
- Company
- Leadership
- History
- Fondation Ipsen
Science
- Science
- Oncology
- Rare Disease
- Neuroscience
- Products
- R&D
- Pipeline
- Clinical Trials
- Lay Summaries
Sustainability
- Sustainability
- Sustainability
- Environment
- Patients
- People
- Governance
- Our Standards
Patients
Stories

Home
Stories
Press Releases story

Ipsen announces the launch of an Employee Shareholding Plan

Back

Post navigation

Ipsen announces the launch of an Employee Shareholding Plan

Ipsen announces the launch of an Employee Shareholding Plan

- 01 June 2021 - 0 mins read

Post navigation

Related Documents

Ipsen announces the launch of an Employee Shareholding Plan (467 KB)

Related stories

Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission

29 June 2022 6 mins read

Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission

IPN price

€107.60

€0.20 (0.19%)

Media
Investors
Partnering
Careers

Company
Sustainability
Patients
Stories

Annual Report
Contact us

Terms and Conditions
Cookie Policy
Global Privacy Policy

Copyright © Ipsen Pharma. All rights reserved - 2024

You are now leaving the Ipsen group website. To continue, please click on Continue?